Baxter International Inc. BAX
Composite 42/100; the shares have moved about 42% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 22/100 — a strong mark against it.
Momentum ranks 71/100 — a moderate point in its favour.
Quality ranks 22/100 — a strong mark against it. Income ranks 35/100 — a moderate mark against it. Valuation ranks 42/100 — a slight mark against it.
What the company does Baxter International Inc. (BAX) supplies medical instruments and supplies across hospitals, dialysis centers, and home care settings. Its portfolio spans IV solutions, infusion systems, surgical tools, patient monitoring devices, and generic injectables. The company serves acute and chronic care markets through direct sales, distributors, and specialty pharmacies.
Key financials Profitability metrics are mixed: ROE -14% and ROA 3% signal weak returns, while gross margin is 34% and operating margin 14%. Revenue grew 5% but net margin is negative at -9%. Leverage is high with Debt/Equity at 1.56 and Net debt/EBITDA at 4.0. Dividend yield is 0.2% with a 2% payout ratio.
Stock health Momentum is positive over 3m 46%, 6m 25%, and 12m 8%, though down 14% from its 52-week high. RSI(14) at 55 indicates neutral momentum. Sideravia scores Quality 23 and Valuation 37, reflecting poor fundamentals despite fair valuation.
Price vs fair value The stock trades at a discount of 10.70% versus the analyst mean target of 28.73. - Recent COO-led surge cited as driver of 3m rally (Zacks) - Interim CFO departure to Cardinal Health noted (MedTech Dive) - Flagged among under-$50 stocks with questionable fundamentals (StockStory) - Rival WST’s strong rally highlighted, drawing sector comparisons (Zacks)
Looking forward Forward P/E of 14.24 suggests moderate earnings expectations. Growth score is 59 but offset by weak profitability and leverage. Momentum remains a relative bright spot amid mixed fundamentals.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.